1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Structure-guided engineering of immunotherapies targeting TRBC1 and TRBC2 in T cell malignancies
(
- Contribution to journal › Article
- 2022
-
Mark
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
(
- Contribution to journal › Article